درباره این اپیزود

انگلیسی
ایالات متحده آمریکا

رونوشت 🔗

جستجوی اپیزودهای گذشته

اپیزودهای قبلی Artificial Intelligence in Drug Discovery را جستجو کن.

قسمت های دیگر در این پادکست

On this episode, I speak with Leila Pirhaji, founder and CEO of ReviveMed ( www.revive-med.com ). ReviveMed uses artificial intelligence to unlock the therapeutic potential of metabolomics. Before learning about ReviveMed, I knew little about metabolomics. Leila is an articulate and enthusiastic te…
On this episode, I speak with Mostapha Benhenda of Startcrowd ( http://www.startcrowd.club ). In January, Mostapha wrote a controversial article critiquing several research labs ( https://bit.ly/2qINvQ9 ). Some accused him of using the article just to promote his service. Others agreed with his cri…
On this episode, I speak with Shai Shen-Orr, cofounder and chief scientist of CytoReason ( www.cytoreason.com ). CytoReason has created a machine learning model of the immune system. This model can integrate data from multiple sources to support drug discovery, the creation of diagnostic tools, and…
On this episode, I speak with Mauro Cozzi, co-founder of Researchably ( www.researchably.com ). Researchably is a biomedical search engine that uses artificial intelligence to save researchers time—Mauro says up to 90%—searching for scientific papers. I spoke with Mauro about how Researchably got s…
For the inaugural episode of Artificial Intelligence in Drug Discovery, I spoke with Dekel Gelbman, CEO of FDNA ( https://www.fdna.com/ ). FDNA enables precision medicine by using artificial intelligence for next-generation phenotyping. Their technology links genetic traits with phenotypic characte…
سلب مسئولیت: پادکست و آثار هنری تعبیه شده در این صفحه متعلق به Simon Smith است که متعلق به صاحب آن است و به Listen Notes، Inc وابسته یا تایید نشده است.